


This article was downloaded by: [Institute Of Atmospheric Physics]
On: 09 December 2014, At: 15:33
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Coordination Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/gcoo20>

Novel μ_2 -oxo-bridged dinuclear aryltelluronic triorganotin(IV) esters: syntheses, structural characterizations, and in vitro cytotoxicity

Ru-Fen Zhang^a, Pei-Zhen Yan^a, Qian-Li Li^a & Chun-Lin Ma^a

^a School of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng, PR China

Accepted author version posted online: 21 Feb 2014. Published online: 24 Mar 2014.



CrossMark

[Click for updates](#)

To cite this article: Ru-Fen Zhang, Pei-Zhen Yan, Qian-Li Li & Chun-Lin Ma (2014) Novel μ_2 -oxo-bridged dinuclear aryltelluronic triorganotin(IV) esters: syntheses, structural characterizations, and in vitro cytotoxicity, *Journal of Coordination Chemistry*, 67:4, 649-659, DOI: [10.1080/00958972.2014.897337](https://doi.org/10.1080/00958972.2014.897337)

To link to this article: <http://dx.doi.org/10.1080/00958972.2014.897337>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &


Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Novel μ_2 -oxo-bridged dinuclear aryltelluronic triorganotin (IV) esters: syntheses, structural characterizations, and *in vitro* cytotoxicity

RU-FEN ZHANG, PEI-ZHEN YAN, QIAN-LI LI and CHUN-LIN MA*

School of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng, PR China

(Received 4 November 2013; accepted 31 January 2014)



Four new μ_2 -oxo-bridged dinuclear aryltelluronic triorganotin esters $[\text{ArTe}(\mu\text{-O})(\text{OH})(\text{OSnR}_3)_2]_2$ (Ar = *n*-propyl-Ph, R = Me: **1**, R = Ph: **2**; Ar = *i*-propyl-Ph, R = Me: **3**, R = Ph: **4**) were synthesized by reaction of μ_2 -oxo-bridged dinuclear aryltelluronic acids and the corresponding R_3SnCl (R = Me, Ph) with potassium hydroxide in methanol. The complexes were characterized by X-ray crystallography, elemental analysis, FT-IR, and NMR (^1H , ^{13}C , ^{119}Sn) spectroscopy. The structural analysis indicates that these complexes are isostructural and crystallized as Sn_4Te_2 molecules, in which the asymmetric four-membered $\text{Te}_2(\mu_2\text{-O})_2$ units are situated in the center. The geometry of tellurium is described as a distorted octahedron and each tin is described as a distorted tetrahedron. Complex **2** has a 2-D network structure connected by intermolecular C–H $\cdots\pi$ interactions. Complexes **1–4** were tested for *in vitro* cytotoxicity against human lung cancer cells (A549) and human hepatocellular carcinoma cells (HepG2).

Keywords: Organotin(IV); Aryltelluronic acids; X-ray crystallography; Structural characterization; Cytotoxic activity

1. Introduction

Organotin derivatives have attracted attention for structural diversity, various coordination modes, and tumor-inhibiting activities [1–3]. Since antitumor activities of organotin complexes were discovered by Gielen [4], a series of traditional organotin derivatives including organotin carboxylate, organotin phosphonate, organotin sulfonate, and organotin selenate

*Corresponding author. Email: macl856@163.com

have been investigated for their biochemical activities [5–8]. However, only a few complexes of organotin tellurate are involved. According to reports [9], the bioactive properties of tellurium have attracted a lot of interest, since the biochemical mechanisms of tellurium cytotoxicity are beginning to emerge. Some organic tellurium compounds have good effects on the body just as antilipid peroxidation [10], anticarcinoma activity [11], and leukemia cell proliferation inhibition [12]. With these in mind, we turn our attention to incorporate bioactive Te into the structures of organotin complexes to obtain organotin tellurate as a strategy of preparation of new drug candidates in which the metal and the aryltelluronic ligands could act synergistically. Herein, μ_2 -oxo-bridged dinuclear aryltelluronic acids were synthesized [13, 14], followed by treatment with triorganotin chloride in a 1 : 4 ratio which successfully afforded dinuclear aryltelluronic triorganotin esters $[\text{ArTe}(\mu\text{-O})(\text{OH})(\text{OSnR}_3)_2]_2$ (Ar = *n*-propyl-Ph, R = Me: **1**, R = Ph: **2**; Ar = *i*-propyl-Ph, R = Me: **3**, R = Ph: **4**). The complexes were characterized by X-ray crystallography, elemental analysis, FT-IR and NMR (^1H , ^{13}C , ^{119}Sn) spectroscopy, and were tested for *in vitro* cytotoxicity against human lung cancer cells (A549) and human hepatocellular carcinoma cells (HepG2).

2. Experimental details

2.1. Materials and measurements

Trimethyltin chloride and triphenyltin chloride were commercially available and used without purification. μ_2 -oxo-bridged dinuclear aryltelluronic acids were prepared by a standard method [13, 14]. The melting points were obtained with a Kofler micro-melting point apparatus and are uncorrected. Elemental analyses were performed with a PE-2400II apparatus. Infrared spectra were recorded with a Nicolet-5700 spectrometer using KBr disks. ^1H , ^{13}C , and ^{119}Sn NMR spectra were recorded with a Varian Mercury Plus 400 spectrometer operating at 400, 100.6, and 149.2 MHz, respectively. The spectra were acquired at room temperature (298 K), unless otherwise specified. ^{13}C NMR spectra are broadband-proton-decoupled. The chemical shifts are reported in ppm with respect to the references and are stated relative to external tetramethylsilane (TMS) for ^1H and ^{13}C NMR and to tetramethyltin for ^{119}Sn NMR.

2.2. Syntheses of 1–4

2.2.1. [*n*-C₃H₇C₆H₅Te(μ -O)(OH)(OSnMe₃)₂]₂ (1**).** The reaction was carried out under nitrogen by use of standard Schlenk techniques. The μ_2 -oxo-bridged dinuclear 4-*n*-propylbenzenetelluronic acid (0.599 g, 1.0 mM) was added to solution of methanol (30 mL) with potassium hydroxide (0.336 g, 4.0 mM), and the mixture was stirred for 0.5 h. After addition of trimethyltin chloride (1.194 g, 4.0 mM), the mixture was stirred at 50 °C for 12 h and then filtered. The solvent was gradually removed by evaporation under vacuum until a solid product was obtained. The solid was then recrystallized from diethyl ether and colorless crystals of **1** were recovered. Yield: 62%. m.p. 181–183 °C. Anal. Calcd for C₃₀H₆₀O₈Sn₄Te₂: C, 28.18; H, 4.73%. Found: C, 28.07; H, 4.71%. IR (KBr, cm⁻¹): $\nu(\text{-OH})$, 3420; $\nu(\text{Sn-C})$, 546; $\nu(\text{Sn-O})$, 451; $\nu(\text{Te-O-Te})$, 411; $\nu(\text{Te-O})$, 697. ^1H NMR (CDCl₃, ppm): δ 7.85–7.99 (m, 8H, -Ph), 2.95–3.15 (m, 4H, PhCH₂CH₂CH₃), 1.93–2.21

(m, 4H, PhCH₂CH₂CH₃), 0.93 (brs, 6H, PhCH₂CH₂CH₃), 0.37 (s, $^2J_{\text{SnH}} = 29.20$, 36H, Sn(CH₃)₃). ¹³C NMR (CDCl₃, ppm): δ 126.82–131.05 (Ph-C), 34.4 (PhCH₂CH₂CH₃), 30.7 (PhCH₂CH₂CH₃), 14.3 (PhCH₂CH₂CH₃), -5.5 ($^1J_{\text{SnC}} = 351.6$ Hz, Sn-CH₃). ¹¹⁹Sn NMR (CDCl₃, ppm): δ 115.9, 128.4.

2.2.2. [*n*-C₃H₇C₆H₅Te(μ -O)(OH)(OSnPh₃)₂]₂ (2). Complex **2** was prepared in the same method as **1**; triphenyltin chloride (2.313 g, 4.0 mM) was added to 4-*n*-propylbenzenetelluronic acid (0.599 g, 1.0 mM) and potassium hydroxide (0.336 g, 4.0 mM). The reaction mixture was stirred at 50 °C for 12 h and then filtered. The solvent was gradually removed by evaporation under vacuum until the solid product was obtained. Yield: 78%. m.p. 185–187 °C. Anal. Calcd for C₉₀H₈₄O₈Sn₄Te₂: C, 53.42; H, 4.18%. Found: C, 53.23; H, 4.20%. IR (KBr, cm⁻¹): ν (-OH), 3430; ν (Sn-C), 546; ν (Sn-O), 450; ν (Te-O-Te), 404; ν (Te-O), 697. ¹H NMR (CDCl₃, ppm): δ 6.99–7.67 (m, 68H, -Ph and -Ar), 3.47(t, $J = 6.8$ Hz, 4H, PhCH₂CH₂CH₃), 2.17 (brs, 4H, PhCH₂CH₂CH₃), 1.22 (t, 6H, $J = 6.8$ Hz, PhCH₂CH₂CH₃). ¹³C NMR (CDCl₃, ppm): δ 128.1–140.9 (Ph-C), 31.1 (PhCH₂CH₂CH₃), 29.9 (PhCH₂CH₂CH₃), 15.5 (PhCH₂CH₂CH₃). ¹¹⁹Sn NMR (CDCl₃, ppm): δ -108.2, -114.5.

2.2.3. [*i*-C₃H₇C₆H₅Te(μ -O)(OH)(OSnMe₃)₂]₂ (3). Complex **3** was prepared in the same method as **1**. Yield: 57%. m.p. 181–183 °C. Anal. Calcd for C₃₀H₆₀O₈Sn₄Te₂: C, 28.18; H, 4.73%. Found: C, 28.07; H, 4.74%. IR (KBr, cm⁻¹): ν (-OH), 3423; ν (Sn-C), 539; ν (Sn-O), 458; ν (Te-O-Te), 408; ν (Te-O), 696. ¹H NMR (CDCl₃, ppm): δ 7.79–7.91 (m, 8H, Ph), 2.84–2.94 (m, 2H, PhCH(CH₃)₂), 1.19–1.25 (m, 12H, PhCH(CH₃)₂), 0.43 (s, $^2J_{\text{SnH}} = 18.80$ Hz, 36H, Sn(CH₃)₃). ¹³C NMR (CDCl₃, ppm): δ 127.13–150.91 (Ph-C), 34.3 (PhCH(CH₃)₂), 24.1 (PhCH(CH₃)₂), -6.9 ($^1J_{\text{SnC}} = 365.3$ Hz, Sn-CH₃). ¹¹⁹Sn NMR (CDCl₃, ppm): δ 115.5, 128.6.

2.2.4. [*i*-C₃H₇C₆H₅Te(μ -O)(OH)(OSnPh₃)₂]₂ (4). Complex **4** was prepared in the same method as **2**. Yield: 75%. m.p. 186–188 °C. Anal. Calcd for C₉₀H₈₄O₈Sn₄: C, 53.42; H, 4.18%. Found: C, 53.22; H, 4.19%. IR (KBr, cm⁻¹): ν (-OH), 3420; ν (Sn-C), 546; ν (Sn-O), 451; ν (Te-O-Te), 406; ν (Te-O), 697. ¹H NMR (CDCl₃, ppm): δ 6.85–7.68 (m, 68H, -Ph and -Ar), 2.81–2.97 (m, 2H, PhCH(CH₃)₂), 1.20–1.32 (m, 12H, PhCH(CH₃)₂). ¹³C NMR (CDCl₃, ppm): δ 128.2–140.8 (Ph-C), 34.3 (PhCH(CH₃)₂), 24.2 (PhCH(CH₃)₂), ¹¹⁹Sn NMR (CDCl₃, ppm): δ -108.9, -114.8.

2.3. X-ray crystallographic studies

Diffraction data were collected with a Smart CCD area detector with graphite-monochromated Mo-K α radiation ($\lambda = 0.71073$ Å). A semiempirical absorption correction was applied to the data. The structure was solved by direct methods using SHELXS-97 and refined against F^2 by full-matrix least-squares using SHELXL-97 [15]. Hydrogens were placed in calculated positions. Crystal data and experimental details of the structure determinations are listed in table 1.

2.4. In vitro cytotoxicity

Two tumor cell lines (HepG2 and A549) were used to assay the cytotoxicity of the complexes. Cells were inoculated into 96 well plates, with 1×10^4 cells per well. RPMI-1640

Table 1. Crystallographic data and structure refinement parameters for 1–4.

Complex	1	2	3	4
Empirical formula	C ₃₀ H ₆₀ O ₈ Sn ₄ Te ₂	C ₉₀ H ₈₄ O ₈ Sn ₄ Te ₂	C ₃₀ H ₆₀ O ₈ Sn ₄ Te ₂	C ₉₀ H ₈₄ O ₈ Sn ₄ Te ₂
<i>M</i>	1278.74	2023.53	1278.74	2023.53
Crystal system	Triclinic	Monoclinic	Monoclinic	Triclinic
Space group	<i>P</i> -1	<i>C</i> 2/ <i>c</i>	<i>C</i> 2/ <i>c</i>	<i>P</i> -1
<i>a</i> [Å]	12.5852(12)	27.747(2)	23.453(2)	12.9633(11)
<i>b</i> [Å]	13.1006(11)	17.1201(14)	10.5543(7)	13.2105(12)
<i>c</i> [Å]	15.3229(13)	20.2166(17)	21.3711(19)	14.4040(14)
α [°]	70.4380(10)	90	90	108.972(2)
β [°]	87.396(2)	112.979(2)	113.488(2)	104.4310(10)
γ [°]	73.1190(10)	90	90	96.2190(10)
<i>V</i> [Å ³]	2274.2(3)	8841.4(13)	4851.7(7)	2210.3(3)
<i>Z</i>	2	4	4	1
<i>D</i> _{Calcd} (Mg/m ³)	1.867	1.520	1.751	1.520
μ [mm ⁻¹]	3.465	1.815	3.249	1.815
<i>F</i> (0 0 0)	1216	3968	2432	992
Crystal size (mm)	0.64 × 0.38 × 0.32	0.37 × 0.28 × 0.28	0.43 × 0.39 × 0.28	0.42 × 0.35 × 0.26
Reflections collected	14,532	21,961	11,756	10,949
Independent reflections	8023	7805	4277	7600
<i>R</i> _{int}	0.0856	0.0460	0.0549	0.0374
Goodness-of-fit on <i>F</i> ²	1.005	0.801	1.105	1.069
<i>R</i> ₁ [<i>I</i> > 2σ(<i>I</i>)], <i>R</i> ₁ (all data)	0.0883, 0.1716	0.0462, 0.1088	0.0623, 0.1726	0.0563, 0.1565
<i>wR</i> ₂ [<i>I</i> > 2σ(<i>I</i>)], <i>wR</i> ₂ (all data)	0.2062, 0.2869	0.0880, 0.1361	0.0912, 0.2039	0.1081, 0.1923

Table 2. Selected bond lengths (Å) and angles (°) for 1.

Sn(1)–O(1)	2.010(14)	Sn(1)–C(14)	2.09(3)
Sn(1)–C(13)	2.09(2)	Sn(1)–C(15)	2.15(2)
Sn(2)–O(3)	2.007(12)	Sn(2)–C(10)	2.12(2)
Sn(2)–C(11)	2.13(2)	Sn(2)–C(12)	2.15(2)
Te(1)–O(3)	1.894(12)	Te(1)–O(1)	1.914(12)
Te(1)–O(4)	1.964(12)	Te(1)–O(2)	1.966(11)
Te(1)–O(2)#1	1.967(10)	Te(1)–C(7)	2.131(17)
O(2)–Te(1)#1	1.967(10)	Te(1)–O(3)–Sn(2)	126.7(7)
O(3)–Te(1)–O(1)	89.4(6)	O(3)–Te(1)–O(4)	89.0(5)
O(1)–Te(1)–O(4)	176.4(6)	O(3)–Te(1)–O(2)	92.0(5)
O(1)–Te(1)–O(2)	90.2(5)	O(4)–Te(1)–O(2)	86.6(5)
O(3)–Te(1)–O(2)#1	171.3(5)	O(1)–Te(1)–O(2)#1	90.3(5)
O(4)–Te(1)–O(2)#1	90.7(5)	O(2)–Te(1)–O(2)#1	79.3(5)
O(3)–Te(1)–C(7)	96.7(6)	O(1)–Te(1)–C(7)	91.2(6)
O(4)–Te(1)–C(7)	92.2(7)	O(2)–Te(1)–C(7)	171.2(6)
O(2)#1–Te(1)–C(7)	92.1(6)	O(3)–Te(1)–Te(1)#1	131.6(4)
O(1)–Te(1)–Te(1)#1	90.3(4)	O(4)–Te(1)–Te(1)#1	88.3(4)
O(2)–Te(1)–Te(1)#1	39.6(3)	O(2)#1–Te(1)–Te(1)#1	39.6(3)
O(1)–Sn(1)–C(14)	97.1(10)	O(1)–Sn(1)–C(13)	108.2(9)
C(14)–Sn(1)–C(13)	114.4(11)	O(1)–Sn(1)–C(15)	108.3(8)
C(14)–Sn(1)–C(15)	114.2(12)	C(13)–Sn(1)–C(15)	113.0(10)
O(3)–Sn(2)–C(10)	105.3(7)	O(3)–Sn(2)–C(11)	100.2(8)
C(10)–Sn(2)–C(11)	109.0(11)	O(3)–Sn(2)–C(12)	110.6(7)
C(10)–Sn(2)–C(12)	118.1(12)	C(11)–Sn(2)–C(12)	112.0(13)
Te(1)–O(1)–Sn(1)	122.6(6)	Te(1)–O(2)–Te(1)#1	100.7(5)

Note: Symmetry transformations used to generate equivalent atoms: #1 $-x, -y+2, -z+2$; #2 $-x+1, -y+2, -z+1$.

containing antibiotics (100 μg mL⁻¹ streptomycin and 100 U penicillin) and 10% fetal bovine serum were used as the culture medium. After 4 h preincubation of the cells in a

Table 3. Selected bond lengths (Å) and angles (°) for **2**.

Sn(1)–O(1)	1.994(5)	Sn(1)–C(28)	2.145(9)
Sn(1)–C(34)	2.121(9)	Sn(1)–C(40)	2.156(8)
Sn(2)–O(2)	2.011(5)	Sn(2)–C(22)	2.121(9)
Sn(2)–C(16)	2.130(10)	Sn(2)–C(10)	2.138(8)
Te(1)–O(2)	1.907(5)	Te(1)–O(1)	1.920(5)
Te(1)–O(4)#1	1.956(5)	Te(1)–O(3)	1.962(5)
Te(1)–O(4)	1.972(5)	Te(1)–C(7)	2.118(8)
O(4)–Te(1)#1	1.956(5)	Te(1)–O(2)–Sn(2)	120.9(2)
O(2)–Te(1)–O(1)	89.9(2)	O(2)–Te(1)–O(4)#1	92.8(2)
O(1)–Te(1)–O(4)#1	89.6(2)	O(2)–Te(1)–O(3)	86.4(2)
O(1)–Te(1)–O(3)	175.1(2)	O(4)#1–Te(1)–O(3)	87.4(2)
O(2)–Te(1)–O(4)	171.5(2)	O(1)–Te(1)–O(4)	91.6(2)
O(4)#1–Te(1)–O(4)	78.8(2)	O(3)–Te(1)–O(4)	91.6(2)
O(2)–Te(1)–C(7)	99.8(3)	O(1)–Te(1)–C(7)	92.6(3)
O(4)#1–Te(1)–C(7)	167.3(3)	O(3)–Te(1)–C(7)	91.2(3)
O(4)–Te(1)–C(7)	88.6(3)	O(1)–Sn(1)–C(34)	118.1(3)
O(1)–Sn(1)–C(28)	97.9(3)	C(34)–Sn(1)–C(28)	109.0(4)
O(1)–Sn(1)–C(40)	105.1(3)	C(34)–Sn(1)–C(40)	115.0(4)
C(28)–Sn(1)–C(40)	110.4(4)	O(2)–Sn(2)–C(22)	114.9(3)
O(2)–Sn(2)–C(16)	94.8(4)	C(22)–Sn(2)–C(16)	108.8(4)
O(2)–Sn(2)–C(10)	114.6(3)	C(22)–Sn(2)–C(10)	113.4(3)
C(16)–Sn(2)–C(10)	108.4(4)	Te(1)–O(1)–Sn(1)	126.6(3)

Note: Symmetry transformations used to generate equivalent atoms: #1 $-x+1/2, -y+3/2, -z+1$.

Table 4. Selected bond lengths (Å) and angles (°) for **3**.

Sn(1)–O(2)	2.062(9)	Sn(1)–C(14)	2.093(17)
Sn(1)–C(15)	2.109(13)	Sn(1)–C(13)	2.176(17)
Sn(2)–O(3)	2.008(8)	Sn(2)–C(10)	2.109(19)
Sn(2)–C(11)	2.129(19)	Sn(2)–C(12)	2.134(18)
Te(1)–O(2)	1.881(8)	Te(1)–O(3)	1.915(8)
Te(1)–O(4)#1	1.965(8)	Te(1)–O(4)	1.969(8)
Te(1)–O(1)	1.980(8)	Te(1)–C(7)	2.101(13)
O(4)–Te(1)#1	1.965(8)	Te(1)#1–O(4)–Te(1)	101.3(3)
O(2)–Te(1)–O(3)	90.5(4)	O(2)–Te(1)–O(4)#1	92.8(3)
O(3)–Te(1)–O(4)#1	90.1(4)	O(2)–Te(1)–O(4)	171.4(4)
O(3)–Te(1)–O(4)	88.7(3)	O(4)#1–Te(1)–O(4)	78.7(3)
O(2)–Te(1)–O(1)	90.8(4)	O(3)–Te(1)–O(1)	176.8(4)
O(4)#1–Te(1)–O(1)	86.9(3)	O(4)–Te(1)–O(1)	89.7(4)
O(2)–Te(1)–C(7)	96.0(4)	O(3)–Te(1)–C(7)	93.6(4)
O(4)#1–Te(1)–C(7)	170.4(4)	O(4)–Te(1)–C(7)	92.5(4)
O(2)–Sn(1)–C(14)	101.1(6)	O(2)–Sn(1)–C(15)	98.9(5)
C(14)–Sn(1)–C(15)	127.7(7)	O(2)–Sn(1)–C(13)	95.8(6)
C(14)–Sn(1)–C(13)	113.0(8)	C(15)–Sn(1)–C(13)	112.4(7)
O(3)–Sn(2)–C(10)	109.9(6)	O(3)–Sn(2)–C(11)	96.5(6)
C(10)–Sn(2)–C(11)	111.2(9)	O(3)–Sn(2)–C(12)	109.0(6)
C(10)–Sn(2)–C(12)	116.8(10)	C(11)–Sn(2)–C(12)	111.6(8)
Te(1)–O(2)–Sn(1)	128.0(5)	Te(1)–O(3)–Sn(2)	122.1(4)

Note: Symmetry transformations used to generate equivalent atoms: #1 $-x, -y+2, -z$.

humidified 5% CO₂ incubator at 37 °C, the complexes were added with final concentration of 1–200 µg mL⁻¹, followed by further incubation for 24 h. Five mg mL⁻¹ MTT solution dissolved in PBS was added to each well by administering 10 µL per well. The cells were cultured for another 4 h, then the culture medium was discarded. Finally, 100 µL DMSO was added to each well, mixed, and measured at 570 nm.

Table 5. Selected bond lengths (Å) and angles (°) for **4**.

Te(1)–O(2)	1.895(7)	Te(1)–O(1)	1.899(6)
Te(1)–O(3)#1	1.958(7)	Te(1)–O(4)	1.959(6)
Te(1)–O(3)	1.975(6)	Te(1)–C(1)	2.095(10)
Sn(1)–O(1)	2.000(6)	O(3)–Te(1)#1	1.958(7)
Sn(1)–C(22)	2.120(11)	Sn(1)–C(10)	2.135(10)
Sn(1)–C(16)	2.154(11)	Sn(2)–O(2)	2.021(7)
Sn(2)–C(34)	2.115(11)	Sn(2)–C(40)	2.149(11)
Sn(2)–C(28)	2.156(11)	Te(1)#1–O(3)–Te(1)	101.2(3)
O(2)–Te(1)–O(1)	89.5(3)	O(2)–Te(1)–O(3)#1	171.3(3)
O(1)–Te(1)–O(3)#1	90.4(3)	O(2)–Te(1)–O(4)	87.0(3)
O(1)–Te(1)–O(4)	175.4(3)	O(3)#1–Te(1)–O(4)	92.6(3)
O(2)–Te(1)–O(3)	92.5(3)	O(1)–Te(1)–O(3)	89.4(3)
O(3)#1–Te(1)–O(3)	78.8(3)	O(4)–Te(1)–O(3)	87.8(3)
O(2)–Te(1)–C(1)	98.9(4)	O(1)–Te(1)–C(1)	92.5(4)
O(3)#1–Te(1)–C(1)	89.8(3)	O(4)–Te(1)–C(1)	91.0(4)
O(3)–Te(1)–C(1)	168.5(4)	O(1)–Sn(1)–C(22)	116.9(4)
O(1)–Sn(1)–C(10)	104.4(4)	C(22)–Sn(1)–C(10)	117.0(5)
O(1)–Sn(1)–C(16)	97.3(4)	C(22)–Sn(1)–C(16)	105.8(5)
C(10)–Sn(1)–C(16)	114.1(4)	O(2)–Sn(2)–C(34)	113.9(4)
O(2)–Sn(2)–C(40)	114.8(3)	C(34)–Sn(2)–C(40)	111.0(4)
O(2)–Sn(2)–C(28)	96.1(4)	C(34)–Sn(2)–C(28)	111.7(4)
C(40)–Sn(2)–C(28)	108.3(5)	Te(1)–O(1)–Sn(1)	125.7(3)
Te(1)–O(2)–Sn(2)	123.6(4)		

Note: Symmetry transformations used to generate equivalent atoms: #1 $-x, -y+2, -z+1$.

3. Results and discussion

3.1. Syntheses

The syntheses of **1–4** are given in scheme 1.

3.2. General aspects

The synthesis of μ_2 -oxo-bridged dinuclear aryltelluronic acids $[\text{ArTe}(\text{O})(\text{OH})_3]_2$ were carried out according to previously reported methods [13, 14]. Complexes **1–4** have been synthesized by corresponding telluronic acid, potassium hydroxide, and triorganotin chloride R_3SnCl in 1 : 6 : 4, 1 : 6 : 6, and 1 : 6 : 8 ratios in methanol, but only four OSnR_3 were coordinated. Maybe the space stereo-hindrance effect results in this product. Complexes **1–4** are stable in air and in solution. Crystals suitable for X-ray analysis were obtained by slow evaporation of diethyl ether for **1** and **3**. Crystals of **2** and **4** were obtained by slow evaporation of petroleum ether solution.

3.3. IR spectra

IR spectra of **1–4** were recorded 4000–400 cm^{-1} . The stretching frequencies of interest are those associated with the $-\text{OH}$, $\text{Sn}-\text{C}$, $\text{Sn}-\text{O}$, $\text{Te}-\text{O}$, and $\text{Te}-\text{O}-\text{Te}$ groups. The strong absorption at 450–483 cm^{-1} , which is absent in the spectrum of the free ligands, is assigned to $\text{Sn}-\text{O}$ stretch. Absorptions that appear at 404–412 cm^{-1} are assigned to $\text{Te}-\text{O}-\text{Te}$ vibrations, while the absorption bands that appear at 691–697 cm^{-1} are assigned to $\text{Te}-\text{O}$ vibrations [16, 17]. The strong absorptions at 3406–3430 cm^{-1} in these spectra are assigned to the vibrations of unreacted OH [16]. All these values are consistent with those detected in a number of organotin(IV)-oxygen derivatives [18, 19].

3.4. NMR spectra

The ^1H NMR spectra show signals of the $-\text{OH}$ in the spectrum of the ligands are weakened and some are even too weak to be detected in these complexes, revealing removal of some $-\text{OH}$ protons, consistent with the IR data. The ^{13}C NMR spectra of the complexes show a significant downfield shift of all carbon resonances compared with the free ligands because of electron-density transfer from the ligands to metal. These data are consistent with the structures of **1–4**.

The ^{119}Sn NMR spectra of complexes can be divided into two groups. One group is between 115.5 and 128.6 ppm (**1** and **3**). As reported [20], δ values for ^{119}Sn NMR spectra from -40 to 200 ppm have been associated with four-coordinate alkyltin centers. Thus, we conclude that **1** and **3** are four coordinate. The other group is between -108.2 and -114.8 ppm (**2** and **4**). According to literature [21], δ for ^{119}Sn NMR spectra in the -60 to -120 ppm range are associated with four-coordinate aryltin centers. Therefore, **2** and **4** are also typically four coordinate.

3.5. Description of crystal structures of 1–4

The solid-state structures of **1–4** are depicted in figures 1–4, while selected bond lengths and angles of **1–4** are summarized in tables 2–5, respectively. As can be seen from figures 1–2 and 3–4, the structures of **1–4** are similar, with only small differences in angles and bond lengths. Therefore, we choose **1** as an example to describe the structures of these complexes. The molecular structure of **1** (figure 1) displays an almost planar four-membered Te_2O_2 core. The spatial arrangement of $\text{Te}(1)$ is distorted octahedral, the equatorial plane






Figure 1. Molecular structure of **1**.

Figure 2. Molecular structure of **2**.Figure 3. Molecular structure of **3**.

defined by one C from aryl, one O(3) from OSnR₃, and two O from Te₂O₂, while the axial positions are occupied by another O(1) from OSnR₃ and one O from OH. The sum of the angles subtended at Te(1) (360.1°) in the equatorial plane is typical; the axial-Te(1)-axial angle (176.4(6)°) slightly deviates from the normal angle of 180°, suggesting some distortion from an ideal octahedron. Each tin in **1** forms four primary bonds, three from the methyl carbons and one from bridging O. The bond angles around Sn(1) and Sn(3) range from 97.1(10)° to 118.1(12)°, suggesting distortion from an ideal tetrahedron. Both Sn–O distances [Sn(1)–O(1) 2.010(14) Å, Sn(2)–O(3) 2.007(12) Å] are shorter than the sum of the covalent radii of Sn and O (2.13 Å) [22], and much shorter than the sum of the van der




Figure 4. Molecular structure of **4**.





Figure 5. 2-D network structures of **2** with intermolecular C-H... π interactions.

Waals radii 3.69 Å [23], which proves that oxygens are coordinated to Sn by strong chemical bonds. The Sn–C bond lengths [2.09(2)–2.15(2) Å] are consistent with those reported in other triorganotin complexes [24].

As for the four-membered Te₂O₂ core of **1–4**, data are comparable with those reported in the dinuclear *m*-terphenyltellurinic acid [2,6-Mes₂C₆H₃Te(μ -O)(OH)]₂ and the dinuclear *m*-terphenyltelluronic acid [2,6-Mes₂C₆H₃Te(μ -O)(OH)₃]₂ [14], in which the typical Te-(μ -O) single bond lengths of **1–4** (1.956(5)–1.975(6) Å), Te-(μ -O)-Te internal angles



Ar = 4-n-propyl-Ph, R = Me, **1**; Ar = 4-n-propyl-Ph, R = Ph, **2**;
 Ar = 4-i-propyl-Ph, R = Me, **3**; Ar = 4-i-propyl-Ph, R = Ph, **4**.

Scheme 1.

between 100.7(2) and 101.3(17)°, and (μ -O)-Te-(μ -O) internal angles between 78.7(3) and 79.3(5)°. The average Te-(μ -O) distance in the four-membered Te₂O₂ ring is 1.966 Å, whereas the terminal Te–O bonds (O from OH) are about 0.003 Å longer, which are significantly shorter than the average ‘standard Te–O single bonds’ of [(4-MeOC₆H₄)₂TeO]_n (2.063(2) Å) [25].

In the case of **2**, intramolecular C–H··· π interactions lead to a 2-D polymeric assembly, which is shown in figure 5.

3.6. Cytotoxic activities

The cytotoxicity *in vitro* of **1–4** and cisplatin against two different cell lines, human lung carcinoma cell line (A549), and human hepatocellular carcinoma cell line (HepG2), have been evaluated by MTT-based assays. The IC₅₀ values, calculated from the dose survival curves obtained after 12 h of drug exposure (MTT test), are shown in table 6. As can be seen from table 6, those complexes with R = Ph (**2** and **4**) exhibit strong activity against A549 or HepG2. The IC₅₀ values for **2** against A549 and HepG2 are 1.4 and 1.2 $\mu\text{g mL}^{-1}$, respectively, 7 and 18 times more active than that of cisplatin; **4** against A549 and HepG2 are 8 and 15 times stronger than that of cisplatin, respectively. However, those complexes with R = Me (**1** and **3**) display a little more activity against HepG2 (IC₅₀ 15.8, 14.7 $\mu\text{g mL}^{-1}$) than cisplatin, while exhibiting weaker activity towards A549 than cisplatin. On the basis of the data analysis, the cytotoxic activities of triorganotin(IV) complexes (R = Ph, Me) decrease in the order Ph > Me, which is comparable with the result of the recently reported triorganotin carboxylates [26, 27]. The higher cytotoxic activity of **2** and **4** are presumably due to the presence of phenyls which show high lipophilic character and facilitate binding to biological molecules by π ··· π interactions [28, 29]. As the experimental results are preliminary, further study on the cytotoxic activity of these complexes is highly recommended.

Table 6. Half maximal inhibitory concentration ($\mu\text{g mL}^{-1}$) of **1–4** against tumor cell lines.

Complex	IC ₅₀ ($\mu\text{g mL}^{-1}$)	
	A549	HepG2
1	65 ± 1	15.8 ± 0.4
2	1.4 ± 0.03	1.2 ± 0.03
3	64 ± 2	14.7 ± 0.4
4	1.2 ± 0.02	1.4 ± 0.03
CPT	10.1 ± 0.5	22 ± 1

Supplementary material

CCDC 969640 (1), 969641 (2), 969642 (3), and 969643 (4) contain the supplementary crystallographic data for this article. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.

Funding

We thank the National Natural Science Foundation of China [grant number 21371087]; and Natural Science Foundation of Shandong Province [grant numbers ZR2012BM019 and J12LD13] for financial support.

References

- [1] V. Chandrasekhar, C. Mohapatra, R. Banerjee, A. Mallick. *Inorg. Chem.*, **52**, 3579 (2013).
- [2] M.N. Xanthopoulou, S.K. Hadjikakou, N. Hadjiliadis, E.R. Milaeva, J.A. Gracheva, V.Y. Tyurin, N. Kourkoumelis, K.C. Christoforidis, A.K. Metsios, S. Karkabounas, K. Charalabopoulos. *Eur. J. Med. Chem.*, **43**, 327 (2008).
- [3] V. Chandrasekhar, C. Mohapatra, R.J. Butcher. *Cryst. Growth Des.*, **12**, 3285 (2012).
- [4] S.K. Hadjikakou, N. Hadjiliadis. *Coord. Chem. Rev.*, **253**, 235 (2009).
- [5] C.L. Ma, S.L. Zhang, R.F. Zhang. *Polyhedron*, **31**, 478 (2012).
- [6] R. Murugavel, A. Choudhury, M.G. Walawalkar, R. Pothiraja, C.N.R. Rao. *Chem. Rev.*, **108**, 3549 (2008).
- [7] S.L. Li, T.T. Han, J. Yang. *Acta Cryst.*, **E63**, m2865 (2007).
- [8] R.F. Zhang, J. Ru, Z.X. Li, C.L. Ma, J.P. Zhang. *J. Coord. Chem.*, **64**, 4122 (2011).
- [9] L.A. Ba, M. Döring, V. Jamier, C. Jacob. *Org. Biomol. Chem.*, **8**, 4203 (2010).
- [10] L. Engman, J. Persson, K. Vessman, M. Ekström, M. Berglund. *Free Radical Biol. Med.*, **19**, 441 (1995).
- [11] X. Sun, J.R. Wong, K. Song, L.B. Chen. *Clin. Cancer Res.*, **2**, 1335 (1996).
- [12] J.X. Zheng, Y.D. Gong, D.A. Yan, B. Chen. *J. Fir. Mil. Med. Univ.*, **13**, 209 (1993).
- [13] J. Beckmann, J. Bolsinger, P. Finke, M. Hesse. *Angew. Chem. Int. Ed.*, **49**, 8030 (2010).
- [14] J. Beckmann, J. Bolsinger, A. Duthie, P. Finke. *Organometallics*, **31**, 289 (2012).
- [15] G.M. Sheldrick. *SHELXL-97, Program for Structure Solution*, University of Göttingen, Germany (1997).
- [16] A.M. Efimov. *J. Non-Cryst. Solids*, **253**, 95 (1999).
- [17] V. Stefov, B. Šoptrajanov, I. Kuzmanovski, H.D. Lutz, B. Engelen. *J. Mol. Struct.*, **752**, 60 (2005).
- [18] R.R. Holmes, C.G. Schmid, V. Chandrasekhar, R.O. Day, J.M. Holmes. *J. Am. Chem. Soc.*, **109**, 1408 (1987).
- [19] G.K. Sandhu, R. Hundal, E.R.T. Tiekink. *J. Organomet. Chem.*, **412**, 31 (1991).
- [20] M. Nadvornik, J. Holeček, K. Handlíř, A. Lyčka. *J. Organomet. Chem.*, **275**, 43 (1984).
- [21] J. Holeček, M. Nádvořník, K. Handlíř, A. Lyčka. *J. Organomet. Chem.*, **241**, 177 (1983).
- [22] A. Bondi. *J. Phys. Chem.*, **37**, 871 (2001).
- [23] S.S. Batsanov. *Inorg. Mater.*, **68**, 44 (1964).
- [24] C.L. Ma, Q.F. Wang, R.F. Zhang. *Eur. J. Inorg. Chem.*, **2008**, 1926 (2008).
- [25] J. Beckmann, D. Dakternieks, A. Duthie, F. Ribot, M. Schürmann, N.A. Lewcenko. *Organometallics*, **22**, 3257 (2003).
- [26] H.W. Wang, D.C. Li, M. Hong, J.M. Dou. *J. Organomet. Chem.*, **740**, 1 (2013).
- [27] Sadiq-ur-Rehman, S. Ali, A. Badshah, M. Mazhar, X.Q. Song, G. Eng, K.M. Khan. *Synth. React. Inorg. Met. Org. Chem.*, **1379**, 34 (2004).
- [28] M.A. Salam, M.A. Affan, F.B. Ahmad, M.D. Azharul Arafath, M. Ibrahim Mohamed Tahir, M.B. Shamsuddin. *J. Coord. Chem.*, **65**, 3174 (2012).
- [29] M. Hussain, M.S. Zia-Ur-Rehman, M. Altaf, H. Stoeckli-Evans, S. Ali. *J. Coord. Chem.*, **66**, 868 (2013).